Linked Data API

Show Search Form

Search Results

1129746
star this property registered interest false more like this
star this property date less than 2019-06-04more like thismore than 2019-06-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Diabetes: Medical Equipment more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what plans he has to increase access to the Freestyle Libre monitoring device for diabetes patients. more like this
star this property tabling member constituency York Outer more like this
star this property tabling member printed
Julian Sturdy more like this
star this property uin 259980 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove maximum value filtermore like thisremove minimum value filter
star this property answer text <p>Glucose monitoring technology, such as flash glucose monitors like Freestyle Libre will continue to be available to those meeting the relevant clinical criteria.</p><p>The NHS Long Term Plan announced that the National Health Service will ensure that, in line with clinical guidelines, eligible patients with type 1 diabetes benefit from life changing flash glucose monitors from April 2019, ending the variation patients in some parts of the country are facing.</p><p>NHS England has published detailed criteria and supporting guidance at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding-v1.1.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding-v1.1.pdf</a></p><p> </p><p>Clinical commissioning groups (CCGS) will be reimbursed for the cost of flash glucose monitoring sensors for those who meet these criteria, which could amount to up to 20% of their type 1 diabetes populations. CCGs can also locally choose to fund flash glucose monitoring for other patients with diabetes. The guidance advises that as part of their annual review process, patients with diabetes should be assessed for suitability for flash glucose monitoring. This process can also form part of a review for a different purpose, if that occurs earlier. This will promote a systematic approach to increasing take up.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 259981 more like this
star this property question first answered
less than 2019-06-12T16:02:36.377Zmore like thismore than 2019-06-12T16:02:36.377Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4079
unstar this property label Biography information for Julian Sturdy more like this
1129747
star this property registered interest false more like this
star this property date less than 2019-06-04more like thismore than 2019-06-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Diabetes: Medical Equipment more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure equitable access to the Freestyle Libre monitoring device for diabetes patients on the NHS. more like this
star this property tabling member constituency York Outer more like this
star this property tabling member printed
Julian Sturdy more like this
star this property uin 259981 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove maximum value filtermore like thisremove minimum value filter
star this property answer text <p>Glucose monitoring technology, such as flash glucose monitors like Freestyle Libre will continue to be available to those meeting the relevant clinical criteria.</p><p>The NHS Long Term Plan announced that the National Health Service will ensure that, in line with clinical guidelines, eligible patients with type 1 diabetes benefit from life changing flash glucose monitors from April 2019, ending the variation patients in some parts of the country are facing.</p><p>NHS England has published detailed criteria and supporting guidance at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding-v1.1.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2019/03/flash-glucose-monitoring-national-arrangements-funding-v1.1.pdf</a></p><p> </p><p>Clinical commissioning groups (CCGS) will be reimbursed for the cost of flash glucose monitoring sensors for those who meet these criteria, which could amount to up to 20% of their type 1 diabetes populations. CCGs can also locally choose to fund flash glucose monitoring for other patients with diabetes. The guidance advises that as part of their annual review process, patients with diabetes should be assessed for suitability for flash glucose monitoring. This process can also form part of a review for a different purpose, if that occurs earlier. This will promote a systematic approach to increasing take up.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 259980 more like this
star this property question first answered
less than 2019-06-12T16:02:36.423Zmore like thismore than 2019-06-12T16:02:36.423Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4079
unstar this property label Biography information for Julian Sturdy more like this
1129860
star this property registered interest false more like this
star this property date less than 2019-06-04more like thismore than 2019-06-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading National Institute for Health and Care Excellence more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what the timescale is for the planned methods and processes review of the National Institute for Health and Care Excellence. more like this
star this property tabling member constituency West Ham more like this
star this property tabling member printed
Lyn Brown more like this
star this property uin 259921 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove maximum value filtermore like thisremove minimum value filter
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technology recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will be subject to a public consultation.</p><p> </p><p>NICE has established a working group consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s senior management team, which in turn will report to the NICE Board.</p><p> </p><p>NICE is in the process of scoping of the review of the methods for technology appraisal and highly specialised technologies evaluations, with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipate being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
259922 more like this
259923 more like this
259924 more like this
star this property question first answered
less than 2019-06-12T16:31:07.383Zmore like thismore than 2019-06-12T16:31:07.383Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1583
unstar this property label Biography information for Ms Lyn Brown more like this
1129861
star this property registered interest false more like this
star this property date less than 2019-06-04more like thismore than 2019-06-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading National Institute for Health and Care Excellence more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, who will lead the planned methods and processes review of the National Institute for Health and Care Excellence. more like this
star this property tabling member constituency West Ham more like this
star this property tabling member printed
Lyn Brown more like this
star this property uin 259922 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove maximum value filtermore like thisremove minimum value filter
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technology recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will be subject to a public consultation.</p><p> </p><p>NICE has established a working group consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s senior management team, which in turn will report to the NICE Board.</p><p> </p><p>NICE is in the process of scoping of the review of the methods for technology appraisal and highly specialised technologies evaluations, with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipate being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
259921 more like this
259923 more like this
259924 more like this
star this property question first answered
less than 2019-06-12T16:31:07.507Zmore like thismore than 2019-06-12T16:31:07.507Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1583
unstar this property label Biography information for Ms Lyn Brown more like this
1129863
star this property registered interest false more like this
star this property date less than 2019-06-04more like thismore than 2019-06-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading National Institute for Health and Care Excellence more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what opportunities (a) patient groups, (b) parliamentarians and (c) other stakeholders will have to influence the (i) scope, (ii) methodology and (iii) leadership of the planned methods and processes review of the National Institute for Health and Care Excellence. more like this
star this property tabling member constituency West Ham more like this
star this property tabling member printed
Lyn Brown more like this
star this property uin 259923 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove maximum value filtermore like thisremove minimum value filter
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technology recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will be subject to a public consultation.</p><p> </p><p>NICE has established a working group consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s senior management team, which in turn will report to the NICE Board.</p><p> </p><p>NICE is in the process of scoping of the review of the methods for technology appraisal and highly specialised technologies evaluations, with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipate being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
259921 more like this
259922 more like this
259924 more like this
star this property question first answered
less than 2019-06-12T16:31:07.577Zmore like thismore than 2019-06-12T16:31:07.577Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1583
unstar this property label Biography information for Ms Lyn Brown more like this
1129864
star this property registered interest false more like this
star this property date less than 2019-06-04more like thismore than 2019-06-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading National Institute for Health and Care Excellence more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, how he plans to enable the involvement of patient groups in the methods and processes review of the National Institute for Health and Care Excellence. more like this
star this property tabling member constituency West Ham more like this
star this property tabling member printed
Lyn Brown more like this
star this property uin 259924 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove maximum value filtermore like thisremove minimum value filter
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technology recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will be subject to a public consultation.</p><p> </p><p>NICE has established a working group consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s senior management team, which in turn will report to the NICE Board.</p><p> </p><p>NICE is in the process of scoping of the review of the methods for technology appraisal and highly specialised technologies evaluations, with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipate being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
259921 more like this
259922 more like this
259923 more like this
star this property question first answered
less than 2019-06-12T16:31:07.623Zmore like thismore than 2019-06-12T16:31:07.623Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1583
unstar this property label Biography information for Ms Lyn Brown more like this
1129739
star this property registered interest false more like this
star this property date less than 2019-06-04more like thismore than 2019-06-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Postnatal Care more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will add the six-week maternal postnatal check to the GP contract. more like this
star this property tabling member constituency Warrington South more like this
star this property tabling member printed
Faisal Rashid more like this
star this property uin 260110 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove maximum value filtermore like thisremove minimum value filter
star this property answer text <p>An agreement on whether additional items will be included in the 2020/21 general practitioner (GP) contract – such as the inclusion of a specific universal maternal six-week postnatal check – will be made following negotiations between NHS England and the GP profession later this year. No decisions have been made on which issues are to be included in the negotiating remit.</p><p>Post-natal care can be delivered by a number of different providers, including midwives, health visitors and GPs. Currently, commissioners and providers should ensure that women are offered a review of their physical, emotional and social wellbeing by a healthcare professional at the end of the postnatal period (between 6-8 weeks). National Institute for Health and Care Excellence guidelines on postnatal care stipulate that a documented, individualised postnatal care plan should be developed with the woman ideally in the antenatal period or as soon as possible after birth.</p><p>The NHS Long Term Plan highlights that we will continue to work with midwives, mothers and their families to implement continuity of carer so that, by March 2021, most women receive continuity of person caring for them during pregnancy, birth and postnatally.</p><p> </p><p> </p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-12T16:33:11.697Zmore like thismore than 2019-06-12T16:33:11.697Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4670
unstar this property label Biography information for Faisal Rashid more like this
1129627
star this property registered interest false more like this
star this property date less than 2019-06-04more like thismore than 2019-06-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Acrylamide: Health Hazards more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps the Government is taking to tackle the threat of cancer from acrylamide in (a) food and (b) tobacco smoke. more like this
star this property tabling member constituency Stroud more like this
star this property tabling member printed
Dr David Drew more like this
star this property uin 259846 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove maximum value filtermore like thisremove minimum value filter
star this property answer text <p>Since the mid-2000s, when acrylamide was first highlighted as a food safety concern, the Food Standards Agency (FSA) has worked with industry and European counterparts to mitigate the risks of acrylamide to consumers. It has developed a Code of Practice for food businesses; provided local authorities with guidance to ensure business compliance; and worked with catering establishments to reduce acrylamide formation during food preparation.</p><p>The FSA continues to take an active role in European Union/United Kingdom negotiations to develop a process for setting regulatory limits for acrylamide in certain products such as those intended for infants and young children.</p><p>The EU does not include acrylamide in its list of priority additives contained in cigarettes and roll-your-own tobacco that are subject to enhanced reporting obligations under the EU Tobacco Products Directive (2014/40/EU).</p><p>The best way to reduce the risk from tobacco smoke is to reduce smoking. The UK is a world leader in tobacco control, with a comprehensive programme to reduce smoking prevalence, including fiscal measures, a ban on all forms of advertising and promotion, smoke free mass media campaigns, action to tackle illegal tobacco and evidence-based support for smokers to quit.</p><p>In recent years, adult smoking prevalence has been declining at an accelerated rate and the government is working with partners across the healthcare system towards the achievement of a smoke free generation.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-12T16:27:53.563Zmore like thismore than 2019-06-12T16:27:53.563Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
252
unstar this property label Biography information for Dr David Drew more like this
1129633
star this property registered interest false more like this
star this property date less than 2019-06-04more like thismore than 2019-06-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Blood: Contamination more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether there is a Barnett consequential to the existing Northern Ireland infected blood payment scheme. more like this
star this property tabling member constituency South Antrim more like this
star this property tabling member printed
Paul Girvan more like this
star this property uin 260103 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove maximum value filtermore like thisremove minimum value filter
star this property answer text <p>As stated in the letter sent to the Chair of the Infected Blood Inquiry on 30 April 2019, the Government is committed to working with its counterparts in the devolved administrations to look at the issue of parity of support across the United Kingdom. I have written to Richard Pengelly, Permanent Secretary at the Department of Health in Northern Ireland and other counterparts in the other devolved nations inviting them to meet to discuss this issue, and a date is currently being sought for this meeting to take place.</p><p>The recently announced £30 million uplift in payments in England will be coming from existing 2019/20 Department of Health and Social Care’s non-National Health Service budget and is not a new allocation from HM Treasury. There is therefore no Barnett consequential arising from this for the existing Northern Ireland scheme.</p> more like this
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property grouped question UIN 260104 more like this
star this property question first answered
less than 2019-06-12T15:49:51.61Zmore like thismore than 2019-06-12T15:49:51.61Z
star this property answering member
4065
star this property label Biography information for Dame Jackie Doyle-Price more like this
star this property tabling member
4633
unstar this property label Biography information for Paul Girvan more like this
1129634
star this property registered interest false more like this
star this property date less than 2019-06-04more like thismore than 2019-06-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Blood: Contamination more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to the letter dated 30 April 2019 from the Parliamentary Under Secretary of State for Mental Health, Inequalities and Suicide Prevention to Sir Brian Langstaff, Chair of the Infected Blood Inquiry, and the reference in that letter to providing greater parity of support across the United Kingdom, what recent discussions his Department has held with the Department of Health for Northern Ireland. more like this
star this property tabling member constituency South Antrim more like this
star this property tabling member printed
Paul Girvan more like this
star this property uin 260104 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove maximum value filtermore like thisremove minimum value filter
star this property answer text <p>As stated in the letter sent to the Chair of the Infected Blood Inquiry on 30 April 2019, the Government is committed to working with its counterparts in the devolved administrations to look at the issue of parity of support across the United Kingdom. I have written to Richard Pengelly, Permanent Secretary at the Department of Health in Northern Ireland and other counterparts in the other devolved nations inviting them to meet to discuss this issue, and a date is currently being sought for this meeting to take place.</p><p>The recently announced £30 million uplift in payments in England will be coming from existing 2019/20 Department of Health and Social Care’s non-National Health Service budget and is not a new allocation from HM Treasury. There is therefore no Barnett consequential arising from this for the existing Northern Ireland scheme.</p> more like this
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property grouped question UIN 260103 more like this
star this property question first answered
less than 2019-06-12T15:49:51.563Zmore like thismore than 2019-06-12T15:49:51.563Z
star this property answering member
4065
star this property label Biography information for Dame Jackie Doyle-Price more like this
star this property tabling member
4633
unstar this property label Biography information for Paul Girvan more like this